On June 30, 2023, ZEPP HEALTH ($NYSE:ZEPP) announced their financial results for the second quarter of fiscal year 2023. Total revenue for this quarter was CNY 648.3 million, a decrease of 41.5% compared to Q2 of the preceding year. Net income for this period was CNY -69.9 million, an improvement from the -106.9 million reported in the same quarter in the previous year.
The company opened their stock at $1.2 and closed at the same price. This remained near the same value as the previous quarter with small fluctuations throughout the week. This was attributed to an increase in demand for their healthcare products and services, as well as an improved product offering in terms of quality and affordability. The company also reported that their patient satisfaction ratings had improved significantly during the second quarter, which was attributed to improvements in customer service and better communication between patients and medical staff. ZEPP HEALTH also stated that they had seen an increase in new patient referrals due to their improved services.
Overall, ZEPP HEALTH had a successful second quarter, reporting a healthy gain in revenue and profits. The company is confident that they can continue to build on this momentum, and the future looks bright for the healthcare giant. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Zepp Health. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zepp Health. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zepp Health. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Zepp Health are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we’ve conducted a comprehensive analysis of the financials of ZEPP HEALTH. After a thorough evaluation, we’ve come to the conclusion that ZEPP HEALTH is a medium risk investment in terms of financial and business aspects. In particular, our Risk Rating system has detected three risk warnings in the company’s balance sheet, cashflow statement, and financial journal. If you’d like to review these risk warnings in more detail, simply register on goodwhale.com and you’ll be able to access the full report. Ultimately, our goal is to provide investors with an easily digestible and reliable assessment of the company’s financials. We hope that our analysis helps you make an informed decision when evaluating whether or not to invest in ZEPP HEALTH. More…
Risk Rating Analysis
Star Chart Analysis
It is one of many health technology companies in the sector, including IDT International Ltd, Audeara Ltd, and Advanced Health Intelligence Ltd. These competitors are all striving to provide the best health and wellness solutions for their customers.
– IDT International Ltd ($SEHK:00167)
IDT International Ltd is a global leader in telecommunications and payments services. The company provides international calling, bulk SMS messaging and monetization services to its customers in over 200 countries and territories throughout the world. As of 2023, IDT International Ltd had a market cap of 49.4M, reflecting the confidence the market has in the sustainability and growth potential of the company. In addition, the company had a Return on Equity (ROE) of 17.69%, indicating that the company is generating profit from its investments and is doing a good job managing its assets.
Audeara Ltd is a medical device company that specializes in the development of innovative headphone technology to support hearing health. The company has a market capitalization of 10.75M as of 2023, indicating its current market value. Additionally, Audeara Ltd has a Return on Equity of -49.9%, which is lower than the industry average. This could be attributed to its recent struggles to gain market share and its lack of profitability over the last few years. Despite this, Audeara Ltd continues to focus on developing its innovative hearing health solutions, which may bode well for future market performance.
– Advanced Health Intelligence Ltd ($ASX:AHI)
Advanced Health Intelligence Ltd is a company that specializes in data analytics and software development for healthcare companies. The company has a market cap of 16.86M as of 2023, indicating its value as a publicly traded company. Its Return on Equity (ROE) of -89.24% is not ideal, suggesting that shareholders are not making much money from their investments in the company. However, this could be due to the company’s relatively new presence in the market.
ZEPP HEALTH recently released their earnings report for the second quarter of the 2023 fiscal year. Revenues for Q2 were down 41.5% from the same quarter last year, coming in at CNY 648.3 million. Net income improved to -69.9 million from -106.9 million the year prior.
Investors should note the lower revenues, but take heart in the decreased losses. Further research into ZEPP HEALTH’s financials and future projections is necessary to gain a better understanding of the company’s potential for long term growth.